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Objectives: The objective of this study was to test the efﬁcacy of an inhibitor of the New Delhi metallo-b-
lactamase (NDM-1). Inhibiting expression of this type of antibiotic-resistance gene has the potential to restore
antibiotic susceptibility in all bacteria carrying the gene.
Methods: We have constructed a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) that
selectively inhibits the expression of NDM-1 and examined its ability to restore susceptibility to meropenem
in vitro and in vivo.
Results: In vitro, the PPMO reduced the MIC of meropenem for three different genera of pathogens that express
NDM-1. In a murine model of lethal E. coli sepsis, the PPMO improved survival (92%) and reduced systemic bac-
terial burdenwhen given concomitantly withmeropenem.
Conclusions: These data show that a PPMO can restore antibiotic susceptibility in vitro and in vivo and that the
combination of PPMO and meropenem may have therapeutic potential against certain class B carbapenem-
resistant infections inmultiple genera of Gram-negative pathogens.
Introduction
Antibiotic resistance is an escalating, worldwide problem that has
gained urgency in the past decade.Many strains of bacterial patho-
gens have become resistant to multiple antibiotics, and some are
now resistant to all standard antibiotics, making treatment chal-
lenging. From 2001 to 2012, acute-care hospitals reporting at least
one healthcare-associated infection from a carbapenem-resistant
Enterobacteriaceae (CRE) increased from 1.2% to 4.6%1 and the
mortality rate froma CRE infection is estimated to be between 40%
and 50%.2–9 This problem is confounded by a lack of development
and approval of new classes of antibiotics in the last three dec-
ades.10–12
The New Delhi metallo-b-lactamase (NDM-1) is a plasmid-
associated Ambler class B b-lactamase. It was ﬁrst identiﬁed in
2008 in a strain of Klebsiella pneumoniae isolated from a patient in
Swedenwho had acquired the bacterium in India.13 Subsequently,
NDM-1-associated resistance has rapidly spread in a clonal fashion
throughout the world at an alarming rate tomany Gram-negative
pathogens, including Escherichia coli, Pseudomonas aeruginosa
and Acinetobacter baumannii.13–17 NDM-1 is particularly danger-
ous because it confers resistance to some of our most potent anti-
biotics, the carbapenems, and is accompanied by genes encoding
resistance to most, if not all, classes of available antibiotics.13,15,16
Although b-lactamase inhibitors have been approved for combin-
ation use in humans, these are primarily effective for the serine
(class A) and ampC (class C) b-lactamases, and none is effective
againstmetallo-b-lactamases, includingNDM-1.10,18,19
A new strategy to combat antibiotic resistance is to design
therapeutics that silence the expression of speciﬁc antibiotic-
resistance genes. These therapeutics would then be used adjunc-
tively with already-approved antibiotics. Targeting speciﬁc
antibiotic-resistance genes or their mRNA transcripts has advan-
tages. First, interference with human gene expression should be
minimal, since there are no human homologues of antibiotic-
resistance genes.20 In addition, the therapeutic could potentially
target multiple species of bacteria to which the antibiotic-
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resistance gene has spread, and recover the activity of existing
small-molecule antibiotics in a manner analogous to b-lactamase
inhibitors.
Phosphorodiamidate morpholino oligomers (PMOs) are syn-
thetic nucleotide analogues that are thought to prevent transla-
tion of a speciﬁc gene by selectively binding mRNA in an antisense
manner.21–23 The structure differs from DNA by a six-member
morpholino ring that replaces the ﬁve-member deoxyribose ring,
and a charge-neutral phosphorodiamidate linker instead of the
phosphodiester linker. The nucleobase is in the same 10 position.
Currently, we have designed and constructed a PMO targeted to
the gene (blaNDM-1) for the NDM-1 enzyme. This PMO was conju-
gated to an arginine-rich peptide, which improves penetration of
the PMO into bacteria.24,25 We show here a proof of the concept
that this peptide-conjugated PMO (PPMO) targeted to blaNDM-1 can
restore bacterial susceptibility to carbapenems and protectmice in
a lethal model of sepsis when co-administered with meropenem.
To our knowledge, this is the ﬁrst time a gene-speciﬁc therapeutic
targeted toNDM-1 has been shown towork in vivo.
Materials and methods
Reagents
All PPMOs were synthesized and puriﬁed at Sarepta Therapeutics (Corvallis,
OR, USA) as described previously.26 The PPMO nucleobase sequences are:
NDM-1, 50-TCCTTTTATTC; NDM-10, 50-GGCAATTCCAT; and scrambled base
sequence control (Scr), 50-TCTCAGATGGT. Each PPMO was conjugated to
(RXR)4XB, where R is arginine, X is 6-aminohexanoic acid and B is b-alanine.
Meropenem was purchased from Hospira Inc. (Lake Forest, IL, USA), dori-
penem (DoribaxV
R
) from Shionogi and Co. Ltd (Osaka, Japan) and imipenem
fromLKT Laboratories, Inc. (St Paul, MN, USA).
Bacterial strains and growth conditions
E. coli CVB-1 was kindly provided by Dr Gian Maria Rossolini (University of
Siena, Italy). A. baumannii BCT-B-026 and E. coli BCT-B-036were kindly pro-
vided by Dr Patrice Nordmann (University of Fribourg, Switzerland). E. coli
1001728, 1101851, AIS070834 and AIS071077 were kindly provided by Dr
J. Kamile Rasheed (CDC, Atlanta, GA, USA). E. coli NDM1-E was kindly pro-
vided byDr SusanM. Poutanen (Mount Sinai Hospital, Toronto, ON, Canada).
K. pneumoniae BAA-2146 and E. coli W3110 and 25922 were obtained
from ATCC (Manassas, VA, USA). Liquid cultures were grown in either
Mueller–Hinton II (MHII) (cation-adjusted) or LB broth. LB agar was used for
growth on solidmedium. To generate log-phase bacteria for in vivo studies,
single colonies were cultured aerobically in LB broth overnight (18 h) at
37 C with shaking (200 rpm). The bacteria were then diluted 4102 and
cultured for an additional 3 h. We determined cfu by plating serial dilutions
on LB agar plates. Bacterial growth curves (culture volumes of 100 or
200 lL) were measured by spectrophotometer (OD595) at 15 or 30 min
intervals for 8–10 h in 96-well plates at 37 Cwith orbital shaking.
Periplasm extraction
An overnight culture of NDM-1-expressing E. coli CVB-1 was diluted
1102 in MHII and NDM-1 PPMO was added to ﬁnal concentrations of 0,
2, 8 and 32 lM. A control culture included 32 lM of a PPMO with a
scrambled base sequence (Scr). The cultures were grown aerobically at
37 C until mid-log phase (OD595¼0.3 of 100 lL in a 96-well microtitre
plate). The cultures were cooled on ice and then 1.0 mLwas centrifuged at
4103 g, 4 C, for 10 min. The supernatant was discarded and the pellet
was resuspended in 200 lL of ice-cold 0.5 M sucrose. The suspension was
centrifuged as before, and the supernatant was removed and discarded.
The pellet was resuspended in 100 lL of ice-cold 0.1 M Tris-acetate/0.5 M
sucrose/5 mM EDTA (pH 8.2). One hundred microlitres of ice-cold H2O
was added and gently mixed. Themixture was incubated for 10 min on ice
and then 2 lL of 1 M MgSO4/1 mM ZnSO4 was added and gently mixed.
The mixture was centrifuged at 1.5104 g, 4 C, for 10 min. The super-
natant was removed and ﬁltered through a 0.2 lm sterile ﬁltration
cartridge. The total protein concentration was measured by the method
of Bradford.27
Carbapenemase enzymatic activity (disc diffusion
assay)
Each periplasm extract (0.5 lg of protein) was mixed on ice with 2 mg/L
meropenem in a ﬁnal volume of 24 lL, and then incubated at 37 C for
1 h. The mixtures were then immediately cooled on ice. A 20 lL aliquot
of each mixture was transferred to a sterile 6 mm paper disc (Becton,
Dickinson, and Company, Sparks, MD, USA), and then placed on a Petri
dish with a freshly seeded top agar lawn (10 lL of an overnight culture
of E. coli W3110 in 3 mL of LB broth top agar). The Petri dish was incu-
bated aerobically at 37 C for 18 h. The area of no growth surrounding
the disc was measured. A control disc with 20 lL of 2 mg/L meropenem
was placed on the surface of the agar and used to establish themaximal
zone of inhibition (meropenem only). Carbapenemase activity was cal-
culated by subtracting the area of each sample disc from the area of the
meropenem-only control disc, and then dividing by the area of the
meropenem-only control disc.
Blue-Carba test
The Blue-Carba test was performed as described previously.28 CVB-1
was cultured in MHII with the indicated concentrations of PPMO or Scr
for 8 h before being added (5 lL) to the 100 lL test solution [0.04% bro-
mothymol blue (Sigma–Aldrich, St Louis, MO, USA), 0.1 mM ZnSO4,
(Mallinckrodt, St Louis, MO, USA) and 3 g/L imipenem at pH 7.0]. Bacteria
were also added to a negative control solution (only bromothymol blue
and ZnSO4 at pH 7.0) to control for changes in the pH of the solution
from the bacteria or PPMO. Results were quantiﬁed bymeasuring the ab-
sorbance at 620 nm.
MIC assays
The procedure for determining the MIC was based on the microdilution
method of the CLSI.29 Speciﬁcally, overnight cultures in MHII were diluted
to 5105 cfu/mL and used to ﬁll wells of a 96-well microtitre plate (Costar
3370, Corning, NY, USA). Each row included a different, ﬁxed concentration
of the NDM-1 PPMO from 128 to 0 lM. A 2-fold dilution series of merope-
nem was made in each row from 64 to 0 mg/L. Plates were incubated at
35–37 Cwith shaking for 18 h. The ODs of the cultures weremeasured in a
spectrophotometer (OD595). Bacterial viability was determined by plating in
triplicate, dilutions of cultures on LB agar plates and counting cfu.
Ethics
All animal procedures were approved by the Oregon State University
Institutional Animal Care and Use Committee (approval numbers 4355 and
4596) and complywith all local, state and federal laws.
Mouse sepsis model
Female BALB/cmice, aged 6–8 weeks (Jackson Labs, Sacramento, CA, USA)
were randomly assigned to treatment groups, and then infected intraperi-
toneally with 3.0106 cfu of log-phase E. coli CVB-1 in 5% mucin (type
III, Sigma Chemical Co., St Louis, MO, USA) in PBS. Where indicated, NDM-1
PPMO or a non-speciﬁc, scrambled-base PPMO was included (100 lg/
mouse, which is 5 mg/kg) in the bacterial inoculum. Meropenem was
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administered (1 mg/mouse, which is 50mg/kg) subcutaneously to the
groups indicated. Additional doses of PPMO andmeropenemwere given at
6, 12, 18 and 24 h. Mice were monitored up to 5 days post-infection. Body
temperatures of mice were recorded using a tympanic infrared thermom-
eter (Braun Thermoscan Pro 4000, Bethlehem, PA, USA). Blood was col-
lected by venipuncture from the saphenous vein using Microvette CB 300
LH (Sarstedt, Germany) collection tubes. Blood was diluted 1101 in PBS
and serial dilutions were plated on LB agar plates for determination of cfu.
Mice were euthanized when body temperatures fell below 30 C. For
delayed treatment experiments, mice were infected without concomitant
treatment, and then treated subcutaneously with 1 mg of meropenem
and intraperitoneally with 250 lg of PPMO (12.5 mg/kg) at 0.5 or 1 h after
infection. Temperature and survival weremonitored as before. For analysis
of cytokines in the blood and bacterial burden in the spleens, mice were in-
fected and treated as indicated, and then euthanized at 10 h post-
infection. Spleens were collected, homogenized, diluted and plated on LB
agar plates to determine cfu burden in the spleen.
Cytokine analysis
Blood was collected by cardiac puncture, and sera were analysed for cyto-
kines using the Invitrogen Mouse Cytokine 10-Plex Panel (ThermoFisher,
USA) and a Millipore Luminex 200 (EMD Millipore, Germany) with xPonent
software.
Statistical analysis
In vitro data were analysed by the two-tailed Student’s t-test. In vivo data
were analysed by the two-tailed Mann–Whitney U-test for non-parametric
experiments and by the Kaplan–Meier method for survival (log-rank,
Mantel–Cox). All evaluations were conducted using GraphPad Prism v. 6.0
(La Jolla, CA, USA) and results were considered signiﬁcantly different with
P<0.05.
Results and discussion
PPMO inhibits expression of NDM-1 protein
We constructed 11-nucleobase PPMOs that are complementary to
the mRNA of NDM-1 in the region of the Shine-Dalgarno ribosome
binding site (NDM-1) or the start codon (NDM-10).30 The region tar-
geted by the NDM-1 PPMO is 100% conserved in 12 of the 16
sequenced non-coding regions of blaNDM-1 alleles and NDM-10 is
100% conserved in all alleles (Figure 1).31
The effect of the NDM-1 PPMO on expression of NDM-1 was
tested by two different methods of measuring the enzymatic ac-
tivity of NDM-1. The NDM-1 PPMO was added to growing cultures
of E. coli CVB-1, an MDR pathogen that expresses the blaNDM-1.
32
The carbapenemase enzymatic activity in periplasmic extracts
wasmeasured using a disc-diffusion assay. The results show a de-
crease in activity that was proportional to the amount of NDM-1
PPMO added to the growing cultures (Figure 2a and b). Notably,
there was no loss of activity in cultures grown with a non-speciﬁc
scrambled PPMO (Scr), which demonstrates speciﬁcity of the
PPMO. As a control, the NDM-1 PPMO was added directly to a peri-
plasmic extract from an untreated culture. The NDM-1 PPMO had
no direct effect on the enzyme or its carbapenemase activity (data
not shown). This is consistentwith its role as an inhibitor of transla-
tion. The functional activity of the NDM-1 enzyme was also meas-
ured using a secondmethod (Blue-Carba) that employs intact cells
instead of periplasmic extracts. The Blue-Carbamethod uses a pH-
sensitive dye that changes colour (from blue to yellow) when the
b-lactam is hydrolysed by the carbapenemase. We found that
adding the NDM-1 PPMO to a growing culture reduced carbapene-
mase activity in proportion to the concentration added (Figure 2c
and d). The Scr PPMO had no effect. These results show that the
NDM-1 PPMO inhibits blaNDM-1 expression.
PPMO restores susceptibility of E. Coli CVB-1 to
meropenem
The MIC of meropenem was measured with various concentra-
tions of the NDM-1 PPMO. The MIC of meropenem was inversely
proportional to the concentration of PPMO (Figure 3a). At 4 lM
PPMO, theMIC ofmeropenemdecreased 4-fold from16 to 4 mg/L.
Moreover, the initial viability was reduced by>3 logs in the culture
treated with both meropenem and NDM-1 PPMO (Figure 3b).
Importantly, the PPMO alone did not inhibit bacterial growth
(Figure 3c), indicating that the PPMOalone has no antimicrobial ac-
tivity. The NDM-1 PPMOwas effective at lowering the MIC ofmero-
penem for multiple NDM-1-positive strains of E. coli (Figure 3d).
Similar results were found using a second PPMO (NDM-10 PPMO)
that is targeted downstream of the NDM-1 PPMO and en-
tirely within the coding region of blaNDM-1 (Figures 1 and 3d). Both
PPMOs reduced the MIC of meropenem for all strains tested in a
Figure 1. Alignment of partial sequences of all reported NDM alleles, including the 50 non-coding region.31 The start codon is underlined in bold font
and the target regions of the two PPMOs are shaded. An asterisk indicates 100% identical bases in all 16 alleles. All bases in the 50 non-coding region
are 100% identical in all alleles for which sequence in this region is available. Additional accession numbers for 50 non-coding regions of NDM-4, -6
and -8 are KP826707.1, KC887916.2 and JF798502, respectively. 50 Non-coding sequence is not available for alleles 10, 11, 15 and 16.
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dose-dependent fashion. However, the concentration of PPMO
needed to achieve the breakpoint concentration of 4 mg/L for
meropenem33 varied (Figure 3e). It is unknown what causes this
variability among strains, most of which are uncharacterized clin-
ical isolates; indeed, only two of the strains that were tested (CVB-
1 and 1001728) have published information on antibiotic resist-
ancemechanisms.32,34 The observed change in enhanced suscep-
tibility does not seem to be sequence speciﬁc, because both NDM-
1 PPMOs were equally effective among strains (Figure 3d), and the
sequence of blaNDM-1 including its 50 non-coding region was identi-
cal in each of the tested strains (data not shown). Additionally, the
variability among strains does not correlatewith the level of carba-
penemase activity, as measured by the Blue-Carba method (data
not shown). Perhaps these results are caused by differences in
NDM-1mRNA turnover rate,mechanisms controlling expression of
blaNDM-1, or simply redundant mechanism(s) of lactam resistance.
The differing level of susceptibility among strains suggests that
some pathogens may require higher doses of meropenem and/or
PPMO to achieve beneﬁcial clinical outcomes.
Since the blaNDM-1 is clonal and conserved across many bacter-
ial genera, we next determined whether the PPMO would have a
similar effect on additional Gram-negative pathogens. We found
that the NDM-1 PPMO also reduced the MIC of meropenem for
NDM-1-positive strains of A. baumannii (Figure 4a–c) and K. pneu-
moniae (Figure 4d–f) without affecting bacterial viability in the ab-
sence of the antibiotic. A scrambled-sequence PPMO had no effect
on theMIC ofmeropenem for either pathogen (data not shown).
The NDM-1 PPMO also lowered the MIC of two other carbape-
nems, doripenem and imipenem, for CVB-1 (Figure 5a–d). This ef-
fect was speciﬁc to carbapenems because the NDM-1 PPMO had
no effect on the MIC of other classes of b-lactamases, such as the
cephalosporin ceftriaxone (data not shown).
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Figure 2. Carbapenemase activity in E. coli CVB-1 after treatment with NDM-1 PPMO. (a) An example of a microbiological assay for carbapenemase activity,
showing zones of bacterial growth inhibition surrounding discs with meropenem on a lawn of the meropenem-susceptible E. coli W3110. A ﬁxed amount of
meropenemwasmixed with periplasm extracts isolated from cultures treated as indicated below, incubated and then applied to the discs. The discs were then
placed on a seeded lawn of E. coliW3110 and incubated overnight. The periplasm was extracted from cultures of NDM-1-expressing E. coli CVB-1 treated with:
(1) no PPMO; (2) 32 lM Scr PPMO; (3) 32 lMNDM-1 PPMO; (4) 8 lMNDM-1 PPMO; or (5) 2 lMNDM-1 PPMO [(6) E. coliW3110 periplasm extract only; (7) control
disc withmeropenemonly (no periplasm)]. (b) Quantitative analysis of carbapenemase activity from zones of inhibition shown in (a). (c) Representative results of
the Blue-Carba test. Carbapenemase production of CVB-1 grownwith NDM-1 PPMO (PPMO) or Scr PPMO (Scr), and a non-carbapenemase producer, ATCC 25922.
(d) Absorbance of blue colour (620 nm) in the Blue-Carba test shown in (c). Data are represented as themean6 SEM, n¼3. ***P<0.001 and **P<0.01 by two-
tailed Student’s t-test. This ﬁgure appears in colour in the online version of JAC and in black andwhite in the print version of JAC.
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NDM-1 PPMO co-administered with meropenem confers
protection in vivo
The efﬁcacy of the NDM-1 PPMO was evaluated in vivo using a
mouse sepsis model. Mice were infected and treated by intraperi-
toneal injection of a freshly prepared mixture of E. coli CVB-1 and
100 lg of NDM-1 PPMO. Meropenem was then immediately ad-
ministered subcutaneously. Treatments were administered every
6 h post-infection for the ﬁrst 24 h, and the mice were monitored
for survival. The results show92% survival of themice treatedwith
the NDM-1 PPMO andmeropenem combination (Figure 6a). This is
a signiﬁcant increase in survival compared with mice treated with
either agent separately, or with co-administration of a scrambled
PPMO (Scr) and meropenem, all of which died by 18 h. Monitoring
during survival demonstrated that after 6 h mice were healthier,
as assessed by body temperature (Figure 6b) and bacterial burden
in the bloodstream (Figure 6c). Additionally, at 10 h (two doses of
PPMO and meropenem) similar and statistically signiﬁcant reduc-
tions in bacteria in the blood and spleenwere found (Figure 6d and
e). Inﬂammation was also signiﬁcantly reduced at 10 h as indi-
cated by the levels of pro-inﬂammatory cytokines TNFa, IL-2 and
IL-6 in the blood ofmice treatedwithbothNDM-1 PPMOandmero-
penem compared with the controls (Figure 6f). Importantly, the
NDM-1 PPMO alone did not have any signiﬁcant pro-inﬂammatory
effect in vivo.
The response to treatment with NDM-1 PPMO was measured
using various doses (33, 11 or 4 lg) of the NDM-1 PPMO. The re-
sults show that morbidity and mortality were inversely propor-
tional to the dose of NDM-1 PPMO (Figure 7). Co-administration
of 33 lg of NDM-1 PPMO and 1 mg of meropenem protected
over 75% of the infected mice for the duration (5 days) of the
experiment (Figure 7a), reduced the fall in body temperature
(Figure 7b) and signiﬁcantly decreased viable bacteria in the
blood (Figure 7c). Lower doses of PPMO were less effective
but still demonstrated signiﬁcant improvement in survival, body
temperature and bacteraemia as compared with the two nega-
tive controls. These data indicate that the PPMO increased
bacterial susceptibility to antibiotic killing in vivo in a dose-
dependent fashion.
TheNDM-1 PPMOwas tested therapeutically by administering it
post-infection. Groups of mice were infected as described above
and then treated with both meropenem (subcutaneously) and
250 lg of PPMO (intraperitoneally) at 0.5 h or 1 h after infection
and every 6 h thereafter for 24 h. When treatment was delayed
0.5 h post-infection, 75% of the mice treated with both merope-
nem and PPMO survived (Figure 8). This is signiﬁcantly (P<0.01)
more than mice in either of the control groups, which all died by
15 h post-infection. Treatment delayed 1 h was not statistically
signiﬁcant, but there was a trend towards an increase in mean
time to death as compared with the control group that was
treated with Scr PPMO with meropenem (14.8662.454 versus
11.2960.7469 h). A lower dose (100 lg) of the NDM-1 PPMO was
ineffective when ﬁrst administered at 0.5 h post-infection. These
in vivo data demonstrate that the NDM-1 PPMO can be used thera-
peutically, analogously to a b-lactamase inhibitor, and has a pro-
tective effect when administered concurrently with meropenem.
This therapeutic regimen compares favourably with other treat-
ments targeted to NDM-1, particularly with those that have been
tested in highly lethalmodels of infection.35,36 Finally, themaximal
doses used in our experiments (12.5 mg/kg) are in line with previ-
ous human trials with PMOs (16 mg/kg), although further studies
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Figure 3. Susceptibility of E. coli to meropenem in cultures treated with NDM-1 PPMO. (a) MIC of meropenem at various concentrations of NDM-1
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will be needed to assess tolerability with the peptide-conjugated
PMOs (PPMOs).37–39
Conclusions
Here, we have described a proof-of-concept, gene-speciﬁc thera-
peutic targeted to a highly conserved antibiotic-resistance gene.
This PPMO was effective and well-tolerated in vivo, and has a
unique mechanism of action. The strategy of suppressing the ex-
pression of a speciﬁc antibiotic-resistance gene is unique and sig-
niﬁcant for a number of reasons. First, instead of discarding
standard antibiotics that are already approved for clinical use and
searching for yet another new antibiotic, our approach restores
utility to standard, marketed antibiotics that have lost usefulness.
This speaks to antibiotic stewardship and our responsibility to use
therapeutics wisely. Second, PPMOs are a nucleotide-based tech-
nology, which enables rapid sequence-speciﬁc design, synthesis
and testing against bacterial gene targets.
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Figure 4. Susceptibility of other NDM-1-expressing Gram-negative pathogens to meropenem in cultures treated with NDM-1 PPMO. (a and d) MIC of
meropenem as a function of NDM-1 PPMO added to the assay using either A. baumannii BCT-B-026 (a) or K. pneumoniae BAA-2146 (d) as indicator. (b
and e) Bacterial viability in cultures of A. baumannii BCT-B-026 (b) or K. pneumoniae BAA-2146 (e) treated with meropenem, NDM-1 PPMO or both. (c and
f) Growth curves of A. baumannii BCT-B-026 (c) or K. pneumoniae BAA-2146 (f) in the presence (circles) or absence (squares) of NDM-1 PPMO (16 lM).
Bacterial density was measured at OD595 every 30 min. Data are represented as themean6 SEM, n¼5 for A. baumannii and n¼3 for K. pneumoniae.
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Figure 6. In vivo infectious challenge and treatment with meropenem and NDM-1 PPMO. Mice were infected with E. coli CVB-1 and treated at 0, 6,
12, 18 and 24 h post-infection with 1 mg of meropenem (n¼8) (given subcutaneously), 100 lg (5 mg/kg) of PPMO (n¼7) (given intraperitoneally),
both treatments (n¼12), a scrambled PPMO (Scr) with meropenem (n¼11) or PBS (n¼7). (a) Survival and (b) body temperature (9 h post-infec-
tion) were recorded. (c) Bacteria in the blood were measured immediately prior to the 6 h treatment. In separate experiments, groups of mice
(n¼6) were euthanized at 10 h post-infection (4 h after the second treatment) and bacteria in the (d) blood and (e) spleen were measured. (f)
Cytokines were measured in sera sampled 10 h post-infection. For Kaplan–Meier survival curves, ***P<0.001, **P<0.01 and *P<0.05 by log-rank
(Mantel–Cox) test. For other graphs, data are represented as mean6 SEM, ***P<0.001, **P<0.01 and *P<0.05 by two-tailed Mann–Whitney
U-test.
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